FGFR2 and intrahepatic cholangiocarcinoma: A phase II non-randomized study found that for 107 patients with FGFR2 fusion/rearrangement-positive ICC who progressed after receiving gemcitabine-based chemotherapy, patients treated with the FGFR2 inhibitor Pemigatinib had an ORR of up to 36%, with a CR rate of 3%, PR rate of 33%, mPFS of 6.9 months, and mOS of 21.1 months15.